

Supplemental Tables for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Table S1: Treatment and survival of 12 patients with chronic HCV infection

Patient	2 nd therapy	3 rd therapy	4 th therapy	5 th therapy	Cause of death	PFS(m)	OS(m)
Patient 1	Pemetrexed + Carboplatin	Erlotinib	Vinorelbine	Afatinib	Cancer related	5.2	13.6
Patient 2	Pemetrexed + Carboplatin	Erlotinib	Gefitinib+ MSC2156119J	NA	Alive	5.6	37.2
Patient 3	Gefitinib	Pemetrexed	NA	NA	Cancer related	5.4	12
Patient 4	NA	NA	NA	NA	Cancer related	1.4	1.6
Patient 5	Pemetrexed + Cisplatin	Gemcitabine	NA	NA	Cancer related	0.7	5.4
Patient 6	NA	NA	NA	NA	Alive	29.3	30.0
Patient 7	NA	NA	NA	NA	Cancer related	15.8	15.8
Patient 8	Vinorelbine	Erlotinib	NA	NA	Cancer related	6.3	16.3
Patient 9	NA	NA	NA	NA	Cancer related	2.6	2.6
Patient 10	NA	NA	NA	NA	Cancer related	14.1	14.1
Patient 11	Pemetrexed + Cisplatin	Docetaxel	Erlotinib	Vinorelbine	Cancer related	4.0	16.4
Patient 12	NA	NA	NA	NA	Cancer related	16.9	16.9

Abbreviation: NA= not applicable

Supplemental Tables for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Table S2: Post progression treatment

PD(n=187)	No.(% of PD)
Subsequent systemic treatment	153 (81.4%)
Chemotherapy	129 (68.6%)
Paclitaxel	17 (9.0%)
Docetaxel	36 (19.1%)
Platinum-based doublet	112 (59.6%)
Gemcitabine	36 (19.1%)
Vinorelbine	26 (13.8%)
EGFR-targeted	130 (69.1%)
Erlotinib	79 (42.0%)
Afatinib	41 (21.8%)
Gefitinib	25 (13.3%)
AZD9291	11 (6.9%)
EGF816	5 (2.7%)
CO1686	1 (0.5%)
Others	-
With Bevacizumab	10 (5.3%)
Other clinical trials	5 (2.7%)

Supplemental Tables for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Table S3: Grade of hepatotoxicity and HCV status

HCV status	No hepatotoxicity	Grade I hepatotoxicity	Grade II hepatotoxicity
CV (-)	37(21.6%)	106(62%)	28(16.4%)
CV (+)	1(8.3%)	9(75%)	2(16.7%)
Unknown HCV status	14(32.6%)	29(67.4%)	0(0%)

Supplemental Tables for:

Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib

Wei-Yu Liao et al.